{"id":29994,"date":"2022-02-11T14:31:03","date_gmt":"2022-02-11T13:31:03","guid":{"rendered":"https:\/\/www.satt.fr\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/"},"modified":"2022-02-11T14:31:03","modified_gmt":"2022-02-11T13:31:03","slug":"signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros","status":"publish","type":"post","link":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/","title":{"rendered":"Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d&#8217;euros"},"content":{"rendered":"<p><strong>Signia Therapeutics, soci\u00e9t\u00e9 dont la mission est d&#8217;acc\u00e9l\u00e9rer la recherche de m\u00e9dicaments contre les infections et les pathologies respiratoires et incub\u00e9e par PULSALYS, annonce l\u2019attribution d\u2019une Aide au D\u00e9veloppement Deeptech de Bpifrance de 1,7 million d\u2019Euros, pour son programme de d\u00e9veloppement et optimisation de la plateforme propri\u00e9taire de Drug Discovery SIGNATURA. Le programme aid\u00e9, d\u2019un budget global de 3,7 millions d\u2019Euros sur 36 mois, a pour objectif la mont\u00e9e en \u00e9chelle de la plateforme de Drug Discovery SIGNATURA.<\/strong><\/p>\n<p>Ce programme vise \u00e0 \u00e9tendre les capacit\u00e9s et la pr\u00e9dictivit\u00e9 de la plateforme SIGNATURA, en incr\u00e9mentant de fa\u00e7on tr\u00e8s significative sa base de donn\u00e9es propri\u00e9taire de signatures de pathologies et de compos\u00e9s, et en d\u00e9veloppant son infrastructure bioinformatique, ses algorithmes, mod\u00e8les math\u00e9matiques et outils d\u2019Intelligence Artificielle (IA). Le projet inclut \u00e9galement des op\u00e9rations de validation fonctionnelle pr\u00e9-clinique et de reformulation des candidats-m\u00e9dicaments identifi\u00e9s.<\/p>\n<p><em>\u00ab Nous sommes tr\u00e8s heureux du soutien que Bpifrance a accord\u00e9 \u00e0 ce projet d\u2019innovation. La pertinence de notre strat\u00e9gie et notre plateforme ont \u00e9t\u00e9 valid\u00e9es par l\u2019entr\u00e9e d\u2019un premier candidat antiviral \u00e0 large spectre en d\u00e9veloppement clinique. Cette aide va aujourd\u2019hui nous permettre d\u2019acc\u00e9l\u00e9rer la mont\u00e9e en puissance de notre plateforme technologique, de tisser des partenariats avec des laboratoires biopharmaceutiques pour l\u2019identification et la validation de nouveaux candidats-m\u00e9dicaments et d\u2019\u00e9toffer notre pipeline contre les infections et les pathologies respiratoires \u00bb<\/em>, souligne <strong>Angelita de Francisco, CEO de Signia Therapeutics<\/strong><\/p>\n<p>En rupture avec le paradigme classique de la recherche biopharmaceutique, &#8211; un m\u00e9dicament \/ une cible -, Signia Therapeutics privil\u00e9gie une approche de polypharmacologie (chaque mol\u00e9cule poss\u00e8de plusieurs cibles cellulaires diff\u00e9rentes), en mettant en oeuvre une strat\u00e9gie de d\u00e9couverte de candidats-m\u00e9dicaments bas\u00e9e sur la modulation de la r\u00e9ponse globale de la cellule infect\u00e9e ou pathologique. Cette strat\u00e9gie est particuli\u00e8rement pertinente dans le domaine infectieux. Cibler la cellule h\u00f4te, plut\u00f4t que les d\u00e9terminants viraux, permet d&#8217;identifier des candidats antiviraux \u00e0 large spectre, de minimiser le risque d&#8217;\u00e9mergence des r\u00e9sistances qui limitent l\u2019efficacit\u00e9 des antiviraux classiques, et d\u2019en potentialiser l\u2019effet en combinaison.<\/p>\n<p>Signia Therapeutics a pour objectif d\u2019ici \u00e0 fin 2022 d\u2019identifier et d\u2019acc\u00e9l\u00e9rer le transfert en clinique de plusieurs candidats-m\u00e9dicaments propri\u00e9taires ou en collaboration avec des laboratoires biopharmaceutiques.<br \/>Pour financer ses projets la soci\u00e9t\u00e9 poursuit une lev\u00e9e de fonds de S\u00e9rie A d\u2019un montant total de 16 millions d\u2019Euros, avec une premi\u00e8re tranche de 4 millions. La soci\u00e9t\u00e9 N\u00e9ovacs (Euronext Growth Paris : ALNEV) a investi 1,3 million d\u2019Euros dans la soci\u00e9t\u00e9 en octobre 2021.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Signia Therapeutics, soci\u00e9t\u00e9 dont la mission est d&#8217;acc\u00e9l\u00e9rer la recherche de m\u00e9dicaments contre les infections et les pathologies respiratoires et incub\u00e9e par PULSALYS, annonce l\u2019attribution d\u2019une Aide au D\u00e9veloppement Deeptech de Bpifrance de 1,7 million d\u2019Euros, pour son programme de d\u00e9veloppement et optimisation de la plateforme propri\u00e9taire de Drug Discovery SIGNATURA. Le programme aid\u00e9, d\u2019un budget global de 3,7 millions d\u2019Euros sur 36 mois, a pour objectif la mont\u00e9e en \u00e9chelle de la plateforme de Drug Discovery SIGNATURA.<\/p>\n","protected":false},"author":24,"featured_media":29318,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[567,568,604],"tags":[],"class_list":["post-29994","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-en","category-successstories-en","category-startup-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d&#039;euros - R\u00e9seau SATT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sylvain DUC\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/\"},\"author\":{\"name\":\"Sylvain DUC\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\"},\"headline\":\"Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d&#8217;euros\",\"datePublished\":\"2022-02-11T13:31:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/\"},\"wordCount\":493,\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/10\/Signia.png\",\"articleSection\":[\"News\",\"Success Stories\",\"Start-up\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/\",\"url\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/\",\"name\":\"Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d'euros - R\u00e9seau SATT\",\"isPartOf\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/10\/Signia.png\",\"datePublished\":\"2022-02-11T13:31:03+00:00\",\"author\":{\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\"},\"breadcrumb\":{\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#primaryimage\",\"url\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/10\/Signia.png\",\"contentUrl\":\"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/10\/Signia.png\",\"width\":972,\"height\":381},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.satt.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d&rsquo;euros\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.satt.fr\/en\/#website\",\"url\":\"https:\/\/www.satt.fr\/en\/\",\"name\":\"R\u00e9seau SATT\",\"description\":\"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.satt.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca\",\"name\":\"Sylvain DUC\",\"url\":\"https:\/\/www.satt.fr\/en\/author\/sylvain\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d'euros - R\u00e9seau SATT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/","twitter_misc":{"Written by":"Sylvain DUC","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#article","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/"},"author":{"name":"Sylvain DUC","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca"},"headline":"Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d&#8217;euros","datePublished":"2022-02-11T13:31:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/"},"wordCount":493,"image":{"@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/10\/Signia.png","articleSection":["News","Success Stories","Start-up"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/","url":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/","name":"Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d'euros - R\u00e9seau SATT","isPartOf":{"@id":"https:\/\/www.satt.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#primaryimage"},"image":{"@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#primaryimage"},"thumbnailUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/10\/Signia.png","datePublished":"2022-02-11T13:31:03+00:00","author":{"@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca"},"breadcrumb":{"@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#primaryimage","url":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/10\/Signia.png","contentUrl":"https:\/\/www.satt.fr\/wp-content\/uploads\/2020\/10\/Signia.png","width":972,"height":381},{"@type":"BreadcrumbList","@id":"https:\/\/www.satt.fr\/en\/signia-therapeutics-incubee-par-pulsalys-recoit-une-aide-au-developpement-deeptech-de-bpifrance-de-17-million-deuros\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.satt.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Signia Therapeutics, incub\u00e9e par PULSALYS, re\u00e7oit une aide au D\u00e9veloppement DeepTech de Bpifrance de 1,7 million d&rsquo;euros"}]},{"@type":"WebSite","@id":"https:\/\/www.satt.fr\/en\/#website","url":"https:\/\/www.satt.fr\/en\/","name":"R\u00e9seau SATT","description":"Les Soci\u00e9t\u00e9s d&#039;Acc\u00e9l\u00e9ration du Transfert de Technologies","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.satt.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.satt.fr\/en\/#\/schema\/person\/d6cfecbabebe684202068d45b736deca","name":"Sylvain DUC","url":"https:\/\/www.satt.fr\/en\/author\/sylvain\/"}]}},"_links":{"self":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/29994","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/comments?post=29994"}],"version-history":[{"count":0,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/posts\/29994\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media\/29318"}],"wp:attachment":[{"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/media?parent=29994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/categories?post=29994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.satt.fr\/en\/wp-json\/wp\/v2\/tags?post=29994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}